Study on the mechanism of Zang Medicine Ruyi Zhenbao Pill in treating degenerative osteoarthritis
Aim to study the mechanism of action of Ruyi Zhenbao Pill in the treatment of degenerative osteoarthritis(DOA)based on network pharmacology,molecular docking and experimental validation.The active ingredients targets of RZP and disease targets of DOA were collected through databases.The common targets were utilized by mixture of them and the core targets were obtained by constructing the protein-protein interaction(PPI)network.Then the drug-component-core targets-disease network diagram and core component-targets diagram were constructed.The gene ontology(GO)and Kyoto encyclopedia of genes and genomes(KEGG)pathway enrichment analysis were carried.AutoDock Vina software was utilized for combining the core targets and the key ingredients of RZP.Finally,ATDC5 cells were used to construct a cellular inflammation model with lipopolysaccharide,cell viability was assessed by CCK-8 assay,and the mRNA expression of relevant core targets was assessed by qRT-PCR.A total 1602 ingredients were searched from databases,and 31 common targets were obtained.Altogether 31 pathways were screened by KEGG enrichment,mainly including Rheumatoid Arthritis Pathway and Osteoclast differentiation pathway.Molecular docking results indicated that the beta-sitosterol of RAP had a high affinity with the core target to be docked.In vitro experiment suggested that the activity of ATDC5 cells increased significantly compared with the model group.RZP could regulate the mRNA expression of TNF-α,iNOS,COX-2 and IL-6.The synergistic effects of RZP in treating DOA with multi-component,multi-target and multi-pathway,and also provides a pre-experimental basis for clinical application and new drug development.
国家科技期刊平台
NSTL
万方数据
